New therapeutic options for advanced non-resectable malignant melanoma

Simone Stadler; Kasia Weina; Christoffer Gebhardt; Jochen Utikal

doi:10.1016/j.advms.2014.12.002

New therapeutic options for advanced non-resectable malignant melanoma

Standard

New therapeutic options for advanced non-resectable malignant melanoma. / Stadler, Simone; Weina, Kasia; Gebhardt, Christoffer; Utikal, Jochen.

in: ADV MED SCI-POLAND, Jahrgang 60, Nr. 1, 03.2015, S. 83-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Stadler, S, Weina, K, Gebhardt, C & Utikal, J 2015, 'New therapeutic options for advanced non-resectable malignant melanoma', ADV MED SCI-POLAND, Jg. 60, Nr. 1, S. 83-8. https://doi.org/10.1016/j.advms.2014.12.002

APA

Stadler, S., Weina, K., Gebhardt, C., & Utikal, J. (2015). New therapeutic options for advanced non-resectable malignant melanoma. ADV MED SCI-POLAND, 60(1), 83-8. https://doi.org/10.1016/j.advms.2014.12.002

Vancouver

Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. ADV MED SCI-POLAND. 2015 Mär;60(1):83-8. https://doi.org/10.1016/j.advms.2014.12.002

Bibtex

@article{aeb71da4d14047c08493732e30334cd6,

title = "New therapeutic options for advanced non-resectable malignant melanoma",

abstract = "Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.",

keywords = "Antineoplastic Agents, Disease Progression, Humans, Immunotherapy, Melanoma, Skin Neoplasms, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "Simone Stadler and Kasia Weina and Christoffer Gebhardt and Jochen Utikal",

year = "2015",

month = mar,

doi = "10.1016/j.advms.2014.12.002",

language = "English",

volume = "60",

pages = "83--8",

journal = "ADV MED SCI-POLAND",

issn = "1896-1126",

publisher = "Medical University of Bialystok",

number = "1",

}

RIS

TY - JOUR

T1 - New therapeutic options for advanced non-resectable malignant melanoma

AU - Stadler, Simone

AU - Weina, Kasia

AU - Gebhardt, Christoffer

AU - Utikal, Jochen

PY - 2015/3

Y1 - 2015/3

N2 - Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.

AB - Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.

KW - Antineoplastic Agents

KW - Disease Progression

KW - Humans

KW - Immunotherapy

KW - Melanoma

KW - Skin Neoplasms

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.advms.2014.12.002

DO - 10.1016/j.advms.2014.12.002

M3 - SCORING: Review article

C2 - 25596540

VL - 60

SP - 83

EP - 88

JO - ADV MED SCI-POLAND

JF - ADV MED SCI-POLAND

SN - 1896-1126

IS - 1

ER -